Bloomberg BNA’s Corporate Law & Accountability Report is available on the Corporate Law Resource Center. This news service keeps corporate practitioners informed of legal developments of...
By Che Odom
June 1 — A shareholder suing BioScrip Inc. directors over alleged misconduct involving the sale of the company's Exjade drug must meet the demand-futility requirement of state law with respect to a new board that was installed shortly after the lawsuit was filed, the Delaware Chancery Court ruled May 31 ( Park Emps.’ & Ret. Bd. Emps.’ Annuity & Benefit Fund of Chicago v. Smith, 2016 BL 173116, Del. Ch., No. 11000-VCG, 5/31/16 ).
Under Delaware law, investors that file derivative claims must show that they made a pre-suit demand on the board of the company on whose behalf the case is brought, unless doing so would be futile. The chancery court's ruling—written by Vice Chancellor Sam Glasscock—departed from the state's general rule that demand must be assessed as of the day the complaint is filed.
Glasscock noted that the case involved unique facts that have never been litigated under Delaware's demand requirement. Four days after the lawsuit was filed, but before the complaint was served, BioScrip installed a new seven-member board of which only two were named defendants in the action.
“If the old board is the operative board, I must consider whether demand would be futile; if my demand-excusal analysis must consider the new board, the complaint as pled is insufficient to support a finding of demand futility,” the judge wrote. “On consideration, I agree that, in these particular circumstances, the Plaintiff must demonstrate demand futility with respect to the new—that is, the current—board of directors.”
Glasscock deferred a ruling on the defendants' motions to dismiss and gave the plaintiff shareholder—the Park Employees' and Retirement Board Employees' Annuity and Benefit Fund of Chicago—30 days to decide whether to amend its complaint.
The retirement fund's lawsuit alleged misconduct related to a kickback scheme involving Exjade, as well as insider trading arising out of two stock offerings in 2013.
The company faces a securities action brought by shareholders in the U.S. District Court for the Southern District of New York over the public stock offerings (13 CARE 1301, 6/12/15).
To contact the reporter on this story: Che Odom in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Yin Wilczek at email@example.com
The opinion is available at http://ow.ly/KXYP300OCA0.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)